Nowadays, Ixekizumab, as a kind of IL-17A inhibitor, has been applied for severe PV in clinical practice (Tsuda et al., 2016; Craig and Warren, 2020; Gordon et al., 2016). Here, IL17A is linked to acquired polycythemia vera.